Skip to main content

David M. Mott

Advisory Board Member

Mr. Mott joined New Enterprise Associates (“NEA”) in September 2008 as a general partner and leads the healthcare investing practice. NEA is among the largest venture capital firms in the world, with a forty-year track record and almost $20 billion under management. NEA invests across all stages in technology and healthcare, and Mr. Mott’s personal investing practice is primarily focused on biopharmaceutical investments.

Prior to joining NEA, Mr. Mott was president and chief executive officer of biotechnology company MedImmune. He joined MedImmune in 1992 and served in various roles, including president and chief executive officer from October 2000 through June 2008 and previously chief financial officer and president and chief operating officer. Mr. Mott led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. Earlier in his career, he was a vice president in healthcare investment banking at Smith Barney, Harris Upham & Co., Inc.

Mr. Mott earned a B.A. from Dartmouth College.